陇神戎发(300534) - 2021 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2021 was CNY 49,153,540.86, representing a 2.78% increase compared to CNY 47,825,547.91 in the same period last year[8]. - Net profit attributable to shareholders decreased by 8.54% to CNY 191,252.78 from CNY 209,116.41 year-on-year[8]. - The company's operating income for the reporting period reached 49.15 million yuan, an increase of 2.78% compared to the same period last year[18]. - Net profit attributable to shareholders was 191,300 yuan, a decrease of 8.54% year-on-year[18]. - The total profit for the reporting period decreased by 1.23 million yuan, mainly due to increased taxes and sales expenses[16]. - Net profit for Q1 2021 was CNY 239,791.44, a decrease from CNY 983,920.21 in the previous period[43]. - The net profit for the first quarter of 2021 was CNY 6,162.47, compared to a net loss of CNY 733,165.30 in the same period last year[48]. - Operating profit for the first quarter was CNY 7,249.96, with a total profit of CNY 7,249.96, reflecting a significant recovery from the previous year's loss[48]. Cash Flow - The net cash flow from operating activities improved significantly, reaching CNY 3,494,633.35, compared to a negative cash flow of CNY -31,283,159.60 in the previous year, marking a 111.17% increase[8]. - The net cash flow from operating activities increased by 34.78 million yuan compared to the same period last year, primarily due to reduced cash payments for pandemic-related procurement by subsidiaries[16]. - Cash flow from operating activities generated a net cash inflow of CNY 3,494,633.35, a turnaround from a net outflow of CNY 31,283,159.60 in the prior year[51]. - Total cash inflow from operating activities was CNY 59,817,178.07, compared to CNY 58,006,986.86 in the previous year, indicating a slight increase[51]. - Cash outflow for purchasing goods and services was CNY 31,564,933.50, down from CNY 67,410,315.25 in the same period last year[51]. - The company incurred a cash outflow of CNY 50,000,000.00 for debt repayment during the quarter[52]. - The company’s cash flow from financing activities resulted in a net outflow of CNY 50,457,388.88, contrasting with a net inflow of CNY 46,174,351.82 in the same period last year[52]. Assets and Liabilities - Total assets decreased by 5.38% to CNY 820,051,391.96 from CNY 866,661,236.00 at the end of the previous year[8]. - As of March 31, 2021, the company's total assets amounted to CNY 820,051,391.96, a decrease from CNY 866,661,236.00 at the end of 2020, reflecting a decline of approximately 5.36%[33][36]. - The company's current assets decreased to CNY 291,253,231.04 from CNY 333,100,789.72, representing a decline of about 12.58%[33][36]. - Cash and cash equivalents dropped significantly from CNY 118,188,757.06 to CNY 70,759,029.01, a decrease of approximately 40.16%[33][34]. - The company's total liabilities decreased from CNY 127,527,610.66 to CNY 80,677,975.18, a decline of approximately 36.77%[35][36]. - Total liabilities for Q1 2021 were CNY 59,215,150.21, a decrease from CNY 116,669,242.12 in the previous period[39]. - Total equity as of the end of Q1 2021 was CNY 726,000,469.64, slightly up from CNY 725,994,307.17[39]. Expenses - Total operating costs for Q1 2021 were CNY 49,747,703.06, up from CNY 46,714,398.99 in the previous period[42]. - Sales expenses for Q1 2021 were CNY 5,876,879.16, compared to CNY 4,989,124.14 in the previous period[42]. - The company's sales expenses rose by 17.79% compared to the same period last year, attributed to increased market development efforts[16]. - Research and development expenses for Q1 2021 were CNY 1,167,767.56, down from CNY 1,553,247.91 in the previous period[42]. - The company paid CNY 8,033,406.78 in employee compensation, an increase from CNY 6,858,110.97 in the prior year[51]. Shareholder Information - The total number of shareholders at the end of the reporting period was 17,829[11]. - The weighted average return on equity remained stable at 0.03% compared to the previous year[8]. - The equity attributable to the owners of the parent company increased slightly from CNY 729,356,249.06 to CNY 729,547,501.84, an increase of about 0.03%[36]. Regulatory and Compliance - The company has received a production license renewal from the Gansu Provincial Drug Administration, indicating compliance with regulatory standards[25]. - The company reported no violations regarding external guarantees during the reporting period[27][28]. - There were no non-operating fund occupations by controlling shareholders or related parties during the reporting period[28]. - The company has not conducted any research, communication, or interview activities during the reporting period[29]. - The company received a new health food registration certificate for its product, Huangqi Danggui capsules, in Thailand[26]. Market and Risk Factors - The company faces risks from industry policy changes, which could significantly impact the pharmaceutical sector and its operations[20]. - The company is actively enhancing its marketing network and product development to mitigate risks associated with reliance on a single product, which accounts for over 90% of sales revenue[22]. Audit and Standards - The first quarter report for 2021 was not audited[57]. - The company did not apply the new leasing standards for the first quarter of 2021[56]. - There were no retrospective adjustments for prior comparative data under the new leasing standards[57].